The present invention is a method of treating Tourette's Disorder (TD) using GABA ergic drugs that elevate the amount of stored presynaptic GABA and do not significantly increase GABA tone (a continuous background level of GABA signaling) in the brain. The administration of vigabatrin and/or (1S,3S)-3-amino-4-difluoromethylenyl-l-cyclopentanoic acid hydrochloride salt is expressly contemplated.

(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).

Inhibitors of NKCCl, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.

Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.

(1S,3S)-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 can be used to treat addiction and neurological disorders without side effects such as visual field defects caused by vigabatrin (Sabril).

(1S,3S)-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 can be used to treat addiction and neurological disorders without side effects such as visual field defects caused by vigabatrin (Sabril).

The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema induced by an anti-convulsive drug such as vigabatrin. The invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention of brain oede...

The present invention relates to taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin. More particularly the invention relates to a substance selected from the group consisting of taurine a taurine precursor a taurine metabolite a taurine derivative a taurine analog and a substance required for the taurine biosynthesis for the prevention of the irreversible visual effects of vigabatrin.

Compounds bioisoteric to vigabatrin and related methods of use.